Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 7/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20852706 | 1.00 | AOC3 (0.50) | AOC3GRM5RAB9AACHETACR3 | |
| SCHEMBL7529041 | 0.79 | AOC3 (0.61) | AOC3RAB9ACYP2C19 | |
| SCHEMBL26053709 | 0.76 | UBE2M (0.44) | AOC3CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26052811 | 0.76 | HTR2B (0.46) | AOC3 | |
| SCHEMBL31698609 | 0.75 | ALDH1A1 (0.42) | AOC3GRM5RAB9AACHEKCNH2 | |
| SCHEMBL31699077 | 0.75 | ALDH1A1 (0.42) | AOC3GRM5RAB9AACHEKCNH2 | |
| SCHEMBL16035902 | 0.71 | RAB9A (0.43) | AOC3RAB9AACHESIGMAR1CYP2C19 | |
| SCHEMBL16036328 | 0.71 | RAB9A (0.43) | AOC3RAB9AACHESIGMAR1CYP2C19 | |
| SCHEMBL7534038 | 0.71 | AOC3 (0.49) | AOC3RAB9ASIGMAR1 | |
| SCHEMBL7571934 | 0.70 | AOC3 (0.46) | AOC3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | AOC3 3843/4885GRM5 540/4885RAB9A 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.